Need to keep on prime of the science and politics driving biotech at this time? Enroll to get our biotech publication in your inbox.
Good morning. It’s been one 12 months since I started co-authoring this article! It’s been a good time bringing you biotech information each week, and please proceed to ship any concepts and ideas my approach: [email protected].
Additionally, STAT has opened up nominations for our annual Wunderkinds record, which goals to honor among the most promising early-career researchers on the market. When you have somebody in thoughts, nominate them right here.
The necessity-to-know this morning
- Akeso and Summit Therapeutics stated the mixture of its PD-1/VEGF-blocking antibody ivonescimab plus chemotherapy delayed tumor development in sufferers with non-small cell lung most cancers — attaining the first purpose of a Part 3 examine known as Harmoni-6, performed in China.
- Novavax stated it believes its Covid-19 vaccine is approvable, primarily based on latest conversations with the FDA. An FDA choice on the vaccine’s ultimate approval was anticipated on April 1, however has been delayed, elevating issues about political interference in regulatory choices associated to vaccines.
Bristol’s schizophrenia drug disappoints in key trial
Bristol Myers Squibb’s new remedy for schizophrenia didn’t present further advantages to sufferers when given on prime of standard-of-care remedy, a setback for the corporate that had framed the drug as a key development driver.
The remedy, Cobenfy, was accredited final 12 months primarily based on knowledge from three randomized research evaluating the drug to placebo. It was the primary new mechanism-of-action accredited for schizophrenia in a long time.
Within the new trial, Bristol examined to see whether or not Cobenfy may additionally work together with a generic antipsychotic to offer extra aid than one drug alone. The reply, no less than on this examine, was no.
Learn extra from STAT’s Jason Mast.
A twist in Lilly’s battle in opposition to compounded GLP-1s
Eli Lilly filed new lawsuits in opposition to 4 telehealth corporations and their associates, utilizing a brand new line of assault than it has used beforehand in such circumstances. The pharma large accused two of the businesses of partaking within the company apply of medication.
Legal guidelines governing the company apply of medication, that are in place in a number of states together with California, typically ban unlicensed firms from proudly owning or controlling medical practices. The legal guidelines are supposed to guard sufferers from choices which can be influenced by the monetary pursuits of a company over the medical judgement of a well being care supplier.
Within the lawsuits, Lilly has alleged that two telehealth corporations, Mochi Well being and Fella Well being, engaged within the company apply of medication, purportedly with the assistance of affiliated medical teams and compounding pharmacies.
Learn extra from STAT’s Ed Silverman and Katie Palmer.
Sam Waksal is caught up in additional authorized hassle
Bear in mind the title Sam Waksal? The biotech entrepreneur was famously convicted of insider buying and selling in 2003 in a case that additionally led to the imprisonment of Martha Stewart. Now, a brand new lawsuit alleges that he breached his fiduciary duties and engaged in “grossly negligent and reckless conduct” because the chairman, CEO, and largest shareholder of Equilibre Biopharmaceuticals, a biotech targeted on neurological therapies.
One in all Waksal’s “most reckless acts,” in response to the lawsuit, was an incident during which he and different Equilibre staff smuggled into the U.S. a veterinary medication that was unapproved for human use, after which administered it to a severely sick baby “outdoors of accredited protocols and with out the Meals and Drug Administration’s authorization.”
The lawsuit, filed by a trustee for Equilibre, additionally alleged that Waksal and different defendants inappropriately transferred proprietary firm belongings to a different Waksal-controlled biotech firm, Graviton Bioscience. Graviton stated the allegations are “with out advantage.”
Learn extra from STAT’s Adam Feuerstein.
CRISPR’s CEO received an enormous payday
From my colleague Jason Mast: Gene-editing corporations in all places are struggling, however one of many discipline’s most distinguished executives nonetheless simply took residence a major payday. CRISPR Therapeutics disclosed final week that it awarded CEO Sam Kulkarni 400,000 new inventory choices final 12 months, bringing his whole compensation bundle for the 12 months, for accounting functions, to $33 million.
These are paid out over 4 years, slightly than abruptly. (His spendable take-home final 12 months seemed one thing like $11.5 million, by STAT’s calculations.) However the whole bundle places him up with the drug business’s highest paid executives.
Mockingly, Kulkarni acquired the beneficiant bundle partly as a result of the gene-editing sector has been doing so poorly. In 2022, Kulkarni acquired a bundle loaded with performance-based incentives — i.e. shares he receives if CRISPR’s inventory worth hits a sure quantity. Since then, gene-editing corporations have confronted a minor armageddon. CRISPR’s inventory is down round 50% from its 2022 peak and Kulkarni has not acquired any of these efficiency choices and it’s “unlikely that each one or any significant portion of it could vest” by this August, the corporate wrote. (It additionally argued he had beforehand acquired fewer shares than rivals, although he nonetheless took residence over $30 million throughout 2022 and 2023).
So the board awarded Kulkarni, who has been at CRISPR since 2015 and CEO since 2017, new time-based incentives to guarantee he stayed on the firm, it stated. Underneath Kulkarni, CRISPR has weathered the sector’s downturn comparatively properly, sustaining a $3.3 billion valuation and pushing a number of medication into trials to comply with its now accredited sickle cell remedy. However he has additionally overseen two small layoffs over the past couple years and vital C-suite turnover. The corporate is now awaiting knowledge on coronary heart illness within the subsequent couple months.
AstraZeneca joins PhRMA as tariffs loom
PhRMA, the lobbying group for pharmaceutical corporations, introduced yesterday that AstraZeneca joined as a brand new member.
The British firm is taking this step as drugmakers face higher uncertainty round federal insurance policies and regulation beneath the Trump administration, with the specter of tariffs, cuts to FDA personnel who have been key to drug evaluations, and potential modifications to Medicare’s drug worth negotiation course of.
The transfer supplies a small enhance to PhRMA, which has seen membership fall lately after the passage of the Inflation Discount Act in 2022 that allowed Medicare to barter drug costs.
Why one firm hiked the worth of its drug by 150%
Right here’s a latest case that highlights the complexity of drug pricing within the U.S.: A small firm known as Eton Prescribed drugs purchased a drug for a uncommon development dysfunction 4 months in the past, after which rapidly raised the record worth by 150%. The corporate argues that’s the one to maintain the remedy available on the market and make a revenue.
How so? A federal regulation that went into impact in 2024 requires drugmakers to pay penalties to Medicaid once they elevate the worth of a drugs above the inflation price. Eton is selecting to pay that penalty and lose cash on Medicaid sufferers, and so as to compensate for that, it’s counting on producing earnings with business payers by means of a larger record worth.
Learn extra from STAT’s Ed Silverman.
Extra reads
